2025 Remote Patient Monitoring (RPM) Market Analysis: Philips, Medtronic, and Abbott Lead with Cutting-Edge Devices, Worldwide Presence, and Strategic Innovations | Intellectia.AI
2025 Remote Patient Monitoring (RPM) Market Analysis: Philips, Medtronic, and Abbott Lead with Cutting-Edge Devices, Worldwide Presence, and Strategic Innovations
Written by Emily J. Thompson, Senior Investment Analyst
Industry Analysis: The Remote Patient Monitoring (RPM) Companies Quadrant provides a comprehensive evaluation of the global RPM market, highlighting 21 leading companies such as Philips, Medtronic, and Abbott. This analysis emphasizes the role of RPM technologies in reducing healthcare costs and enhancing patient outcomes through home-based care.
Market Dynamics: The report categorizes the RPM market based on components, indications, end users, and regions. It notes that RPM technologies improve healthcare efficiency and reduce hospital workloads, although regulatory challenges across different regions may hinder market growth.
Key Players in the RPM Market
Philips: Koninklijke Philips N.V. stands out as a leader in the RPM sector, leveraging its Connected Care segment to offer advanced patient monitoring systems that enhance clinical workflows and minimize hospital readmissions.
Medtronic: Renowned for its extensive medical device portfolio, Medtronic leads in revenue and invests heavily in RPM innovations, focusing on collaborations and acquisitions to strengthen its market position.
Abbott: Abbott Laboratories excels in chronic disease management through its Diagnostic Products and Medical Devices segments, ensuring a broad market reach and continuous innovation in healthcare solutions.
Trends and Challenges
Technological Advancements: The RPM market is witnessing significant growth driven by digital innovations, the rise of telehealth, and the increasing prevalence of chronic diseases. The demand for cost-effective healthcare solutions is also on the rise.
Regulatory and Behavioral Barriers: High investment costs, lack of IT expertise, and behavioral challenges related to healthcare affordability are identified as major restraints. Additionally, the 2024 CMS regulations present further challenges for market expansion.
Opportunities for Growth: The emergence of AI and machine learning, along with a shift towards outpatient care and hospital-at-home programs, presents new opportunities for RPM technologies.
Competitive Landscape
Evaluation Criteria: The 360 Quadrant evaluates RPM companies based on revenue, geographic presence, growth strategies, and sales strategies. The analysis includes a detailed company evaluation matrix categorizing firms into stars, emerging leaders, and pervasive players.
Investment in Innovation: Key players are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation and maintain a competitive edge in the rapidly evolving RPM market.
Conclusion
Future Outlook: The RPM market is poised for growth, driven by technological advancements and increasing demand for remote healthcare solutions. However, stakeholders must navigate regulatory challenges and invest in innovative technologies to capitalize on emerging opportunities.
MDT
$97.72+Infinity%1D
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
11 Hold
0 Sell
Moderate Buy
Current: 98.570
Low
90.00
Averages
110.47
High
119.00
Current: 98.570
Low
90.00
Averages
110.47
High
119.00
Baird
Neutral
downgrade
$109 -> $103
2025-12-16
New
Reason
Baird
Price Target
$109 -> $103
2025-12-16
New
downgrade
Neutral
Reason
Baird lowered the firm's price target on Medtronic to $103 from $109 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.
Nephron Research
Hold
to
Buy
upgrade
$120
2025-12-08
Reason
Nephron Research
Price Target
$120
2025-12-08
upgrade
Hold
to
Buy
Reason
Nephron Research upgraded Medtronic to Buy from Hold with a $120 price target. The firm says the company's pickup in growth "has legs."
Barclays
NULL -> Overweight
maintain
$109 -> $111
2025-11-20
Reason
Barclays
Price Target
$109 -> $111
2025-11-20
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Medtronic to $111 from $109 and keeps an Overweight rating on the shares. The firm upped estimates following the company's organic growth "beat and raise" quarter.
Wells Fargo
Overweight
maintain
$100 -> $114
2025-11-19
Reason
Wells Fargo
Price Target
$100 -> $114
2025-11-19
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Medtronic to $114 from $100 and keeps an Overweight rating on the shares. The firm notes Q2 organic growth of 5.5% exceeded Street, while EPS beat even with the increased opex spend. Medtronic continues to expect a top-line acceleration into the second half of the year and beyond, Wells adds.
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
